Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China

Table 1 Patient characteristics associated with the included moderate to severe Crohn’s disease patients in real-world study

	IMT, n = 295		CMT, n = 130		P value
Patient characteristics	Mean/%	SD	Mean/%	SD
Demographics
Male proportion	72.2%		64.6%		0.125
Age in yr	34.1	10.9	37.2	11.2	0.004b
BMI range
< 18.5	32.8%		40.0%		0.162
18.5-23.9	56.0%		53.8%		0.689
≥ 24	10.4%		6.2%		0.165
Lifestyle
Non-smoker	85.7%		87.7%		0.592
Non-drinker	81.9%		88.5%		0.093
Marital status
Unmarried	43.2%		32.3%		0.037a
Married	56.0%		67.7%		0.026a
Employment status
Student	13.5%		7.7%		0.090
Full-time	59.1%		54.6%		0.401
Part-time	2.7%		2.3%		0.816
Unemployed	6.9%		1.5%		0.023a
Farmer	1.5%		1.5%		0.996
Retired	3.9%		4.6%		0.724
Unknown	5.8%		18.5%		< 0.001
Missing	6.6%		9.2%		0.345
Disease site at diagnosis
Distal colon	52.9%		34.1%		< 0.001
Terminal ileum	19.5%		48.8%		< 0.001
Colon	9.7%		10.9%		0.729
Upper gastrointestinal and back colon	4.3%		3.1%		0.572
Upper gastrointestinal and ileum end	4.7%		0.8%		0.045a
Upper gastrointestinal tract	0.0%		0.8%		0.158
Previous surgery	29.0%		30.0%		0.831
Previous complication
Perianal abscess	27.4%		13.8%		0.003b
Intestinal fistula	36.3%		14.6%		< 0.001
Intestinal obstruction	18.1%		13.1%		0.203
Extra-intestinal manifestation
Aphthous stomatitis	8.9%		3.8%		0.070
Joint pain	3.1%		3.1%		0.995
Comorbidities
Gallbladder diseases	3.9%		5.4%		0.488
Chronic hepatitis B	3.1%		8.5%		0.020a
Lung nodes	3.9%		2.3%		0.421
Gastroenteritis	1.5%		4.6%		0.071

^aP < 0.05.

^bP < 0.01. BMI: Body mass index; CMT: Conventional maintenance therapy; IMT: Infliximab maintenance therapy; SD: Standard deviation.